<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649060</url>
  </required_header>
  <id_info>
    <org_study_id>OP-108</org_study_id>
    <nct_id>NCT04649060</nct_id>
  </id_info>
  <brief_title>Study of Melphalan Flufenamide (Melflufen) in Combination With Daratumumab in Relapsed Refractory Multiple Myeloma</brief_title>
  <acronym>LIGHTHOUSE</acronym>
  <official_title>A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncopeptides AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncopeptides AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, open-label, Phase 3 multicenter study which will enroll&#xD;
      patients that have Relapsed Refractory Multiple Myeloma and are double refractory to an&#xD;
      Immunomodulatory Drug (IMiD) and a Proteasome Inhibitor (PI) (regardless of the number of&#xD;
      prior lines of therapy), or have received at least 3 prior lines of therapy including an IMiD&#xD;
      and a PI.&#xD;
&#xD;
      Patients will receive treatment of melflufen+dexamethasone+daratumumab or daratumumab until&#xD;
      documented progressive disease, unacceptable toxicity or patient/treating physician decision.&#xD;
      Patients in the daratumumab treatment arm will after confirmed progressive disease have the&#xD;
      option to receive treatment with melflufen+dexamethasone+daratumumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Independent Review Committee will be blinded to treatment assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>time from the date of randomization to the date of first documentation of confirmed progressive disease (PD) or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients who achieve a best confirmed response of stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>12 months</time_frame>
    <description>time from the first evidence of confirmed assessment of sCR, CR, VGPR or PR to first confirmed disease progression, or death due to any cause. DOR is defined only for patients with a confirmed PR or better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Grade of treatment emergent adverse events (TEAE).</measure>
    <time_frame>13 months</time_frame>
    <description>Serious Adverse Events will be collected from signing of the Informed Consent until 30 days after last dose of study treatment or initiation of subsequent therapy whichever occurs first. AEs will be collected from the start of study treatment until 30 days after the last dose of any study drug or initiation of subsequent therapy whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Response</measure>
    <time_frame>12 months</time_frame>
    <description>proportion of patients with sCR, CR, VGPR, PR, Minimal Response (MR), Stable Disease (SD), PD or non-evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>12 months</time_frame>
    <description>the proportion of patients who achieve a best confirmed response of sCR, CR, VGPR, PR or MR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Clinical Benefit (DOCB)</measure>
    <time_frame>12 months</time_frame>
    <description>(time from first evidence of confirmed assessment of sCR, CR, VGPR, PR, or MR to first confirmed disease progression, or to death due to any cause.) DOCB is defined only for patients with a confirmed MR or better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>12 months</time_frame>
    <description>Time from randomization to the date of the first documented confirmed response in a patient who has responded with ≥PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>12 months</time_frame>
    <description>Time from the date of randomization to the date of the first documented confirmed PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment (TTNT)</measure>
    <time_frame>12 months</time_frame>
    <description>Time from randomization to the date of next anti-myeloma treatment or until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months (24 months follow-up after progression)</time_frame>
    <description>time from date of randomization to death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Relapse Multiple Myeloma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Study Treatment Arm A (melflufen+dexamethasone+daratumumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be given in cycles and may be given in an outpatient treatment setting. Each cycle is 28 days.&#xD;
Melflufen 30 mg i.v. infusion at Day 1 of each cycle&#xD;
Dexamethasone 40 mg p.o. weekly (if ≥75 years 20 mg weekly).&#xD;
Daratumumab 1800 mg s.c. Cycle 1 and 2: Day 1, 8, 15 and 22. Cycle 3 to 6: Day 1 and 15. Cycle 7+: Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Treatment Arm B (daratumumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment will be given in cycles and may be given in an outpatient treatment setting. Each cycle is 28 days.&#xD;
• Daratumumab 1800 mg s.c. Cycle 1 and 2: Day 1, 8, 15 and 22. Cycle 3 to 6: Day 1 and 15. Cycle 7+: Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan Flufenamide</intervention_name>
    <description>30 mg intravenous (i.v.) infusion</description>
    <arm_group_label>Study Treatment Arm A (melflufen+dexamethasone+daratumumab)</arm_group_label>
    <other_name>Melflufen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg weekly (if ≥75 years 20 mg weekly). Oral tablets</description>
    <arm_group_label>Study Treatment Arm A (melflufen+dexamethasone+daratumumab)</arm_group_label>
    <other_name>Dex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>1800 mg subcutaneous injection</description>
    <arm_group_label>Study Treatment Arm A (melflufen+dexamethasone+daratumumab)</arm_group_label>
    <arm_group_label>Study Treatment Arm B (daratumumab)</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A prior diagnosis of multiple myeloma with documented disease progression after last&#xD;
             line of therapy&#xD;
&#xD;
          -  Double refractory to an immunomodulatory drug (IMiD) and a Proteasome Inhibitor (PI)&#xD;
             (regardless of the number of prior lines of therapy), or have received at least 3&#xD;
             prior lines of therapy including an IMiD and a PI.&#xD;
&#xD;
          -  Prior treatment with daratumumab or another anti-CD38 antibody may be allowed under&#xD;
             certain circumstances&#xD;
&#xD;
          -  Male and women of childbearing potential agrees to use contraception during the&#xD;
             treatment period and during a specified time period after the last dose&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Primary refractory disease (i.e. never responded with at least Minimal Response to any&#xD;
             prior therapy for multiple myeloma)&#xD;
&#xD;
          -  Prior treatment with CD38 CAR-T cell therapy or CD38/CD3 bispecific antibodies&#xD;
&#xD;
          -  Any medical condition that may interfere with safety or participation in this study&#xD;
&#xD;
          -  Other malignancy diagnosed or requiring treatment within the past 3 years with the&#xD;
             exception of adequately treated basal cell carcinoma, squamous cell skin cancer,&#xD;
             carcinoma in-situ of the cervix or breast or very low and low risk prostate cancer in&#xD;
             active surveillance&#xD;
&#xD;
          -  Known or suspected amyloidosis, plasma cell leukemia or POEMS syndrome (plasma cell&#xD;
             dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and&#xD;
             skin changes)&#xD;
&#xD;
          -  Known central nervous system (CNS) or meningeal involvement of myeloma&#xD;
&#xD;
          -  Prior stem cell transplant (autologous and/or allogenic) within 6 months of initiation&#xD;
             of therapy or prior allogeneic stem cell transplantation with active&#xD;
             graft-versus-host-disease&#xD;
&#xD;
          -  Prior treatment with melflufen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria-Victorìa Mateos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario de Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation - Whittier</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists Cancer Center, Salt Lake City</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sveti Georgi&quot;, Plovdiv, Clinical Hematology Clinic</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Sofia, part of Military Medical Academy, Clinic of Hematology and Oncology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Hematological Diseases, Clinic of Hematology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove, 4th Internal Clinic of Hematology</name>
      <address>
        <city>Kralovice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc, Clinic of Hemato-Oncology</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava, Clinic of Hematooncology</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague, 1st Internal Clinic - Clinic of Hematology</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC K. Eristavi National Center of Experimental and Clinical Surgery</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD S.Khechinashvili University Hospital</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malkhaz Katsiashvili Multiprofile EMC LTD</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien-Hospital Siegen gem. GmbH, Dept of Hematology, Medical Oncology and Palliative Medicine</name>
      <address>
        <city>Siegen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra General Hospital, Therapeutic Clinic</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Evangelismos&quot;, Department of Hematology and Lymphoma</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theageneio Anticancer Hospital of Thessaloniki, Department of Hematology</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen Clinical Center, Clinic of Internal Medicine, Department of Hematology</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moritz Kaposi General Hospital, Department of Hematology</name>
      <address>
        <city>Kaposvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Hematology</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Ulleval University Hospital, Oslo Myeloma Center</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Healthcare Facility Municipal Hospitals, Teaching Department of Hematology And Prevention of Neoplastic Diseases</name>
      <address>
        <city>Chorzów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center in Gdansk, Teaching Department of Hematology and Transplantology</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Healthcare Facility University Hospital in Krakow, Teaching Unit of the Hematology Department</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Teaching Hospital No.1 in Lublin, Department of Hematooncology, Bone Marrow Transplantation and Chemotherapy</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaluga Regional Hospital, Department of Hematology</name>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.P. Botkin City Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.A. Semashko Nizhny Novgorod Regional Clinical Hospital, Clinic of Internal Medicine, Department of Hematology</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Reseach Centre, Chemotherapy of Oncohematology Diseases and Bone Marrow Transplantation</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Clinical Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.D. Seredavin Samara Regional Clinical Hospital</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komi Republican Oncology Center</name>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac, Clinic of Hematology</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Oncology Institute</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bratislava St Cyril and Metod</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Martin, Clinic of Hematology and Transfusiology</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona, Department of Hematology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherkasy Regional Oncology Dispensary, Regional Treatment and Diagnostic Hematology Center</name>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chernihiv Medical Center of Modern Oncology, Hematology Department</name>
      <address>
        <city>Chernihiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 4 City Hematology Center</name>
      <address>
        <city>Dnipro</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital No. 9</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv Regional Oncology Center, Center for Hematology and Bone Marrow Transplantation</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Cancer, Research Department of Hemoblastosis Chemotherapy and Adjuvant Treatment Methods, Department of Oncohematology with Adjuvant Treatment Methods Group</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Blood Pathology and Transfusion Medicine, Department of Hematology</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

